Skip to main content
Clinical Trials/NCT01974739
NCT01974739CompletedNot Applicable

Hypernatraemia and Diuretics in Intensive Care Patients

Medical Centre Leeuwarden1 site in 1 country50 target enrollmentStarted: September 2013Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
50
Locations
1
Primary Endpoint
sodium level

Study Overview

Brief Summary

Acquired hypernatremia appears to be associated with mortallity in ICU. To reduce hypernatremia and shorten the time of hypernatremia, we investigate the effect of hydrochloorthiazide compared to a placebo

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • sodium > 142

Exclusion Criteria

  • no informed consent

Arms & Interventions

hydrochloorthiazide

Active Comparator

once a day 25 mg

Intervention: Hydrochloorthiazide (Drug)

placebo

Placebo Comparator

once a day placebo

Intervention: placebo (Drug)

Outcomes

Primary Outcomes

sodium level

Time Frame: 7 days

a decrease of 5 mmol/L sodium in plama

Secondary Outcomes

  • time hypernatraemia(7 days)

Investigators

Sponsor
Medical Centre Leeuwarden
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

E.C. Boerma

MD PhD

Medical Centre Leeuwarden

Study Sites (1)

Loading locations...

Similar Trials